We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Pfizer Inc | NYSE:PFE | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.23 | -0.80% | 28.69 | 28.91 | 28.51 | 28.895 | 26,145,830 | 00:58:54 |
From May 2022 to May 2024
China's top drug regulator said Friday that it approved Merck & Co. and Ridgeback Biotherapeutics' Molnupiravir for emergency use on Thursday, as the country grapples with waves of infections after Beijing abruptly reversed its stringent Covid-19 restrictions earlier this month.
The National Medical Products Administration said it is requiring the approval holder to continue relevant research, complete conditional requirements and submit follow-up research results in a timely manner, according to a statement posted on its website Friday.
Molnupiravir and Pfizer Inc.'s Paxlovid are rival drugs for the treatment of Covid-19. Though Paxlovid pill was found in clinical trials to be more effective than Molnupiravir, the latter is also in high demand as an easy-to-use treatment that can be taken at home.
Write to Singapore Editors at singaporeeditors@dowjones.com
(END) Dow Jones Newswires
December 30, 2022 07:18 ET (12:18 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Pfizer Chart |
1 Month Pfizer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
